{"id":"W4415751687","doi":"10.1016/j.jchf.2025.102706","title":"Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of CRD-740, a PDE9 Inhibitor, in Chronic Heart Failure","year":2025,"lang":"en","type":"article","venue":"JACC Heart Failure","topic":"Phosphodiesterase function and regulation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Heart Institute; University of Alberta","funders":"National Heart, Lung, and Blood Institute; Canadian Institutes of Health Research; Respicardia; American Regent; Sanofi Pasteur; Abbott Vascular; Intas Pharmaceuticals; Institut de Cardiologie de Montréal; Daiichi Sankyo Europe; Servier; Vifor Pharma; MyoKardia; Novo Nordisk; GlaxoSmithKline; Gedeon Richter; Sanofi; Abiomed; Alexion Pharmaceuticals; University of Glasgow; Horizon Therapeutics; Pfizer; Moderna; Sarepta Therapeutics; British Heart Foundation; Duke Clinical Research Institute; Cytokinetics; National Institutes of Health; Regeneron Pharmaceuticals; Defense Acquisition Program Administration; Boston Scientific Corporation; Eli Lilly and Company; Bristol-Myers Squibb; AstraZeneca; CSL Behring; Boehringer Ingelheim; Amgen; Alnylam Pharmaceuticals","keywords":"Heart failure; Natriuretic peptide; Urinary system; Phase (matter); Heart disease; Chronic renal failure","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008169066,0.0003038756,0.0009372662,0.0002671053,0.0001132564,0.00004794406,0.0001464203,0.0003384461,0.00008261143],"category_scores_gemma":[0.0001272868,0.0002529526,0.0003225717,0.0003831221,0.000106185,0.00001670797,0.0001126488,0.0002557854,0.00001475418],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00007938895,"about_ca_system_score_gemma":0.0004112871,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001494333,"about_ca_topic_score_gemma":0.001866371,"domain_scores_codex":[0.9977306,0.0003896464,0.0007693889,0.0005358674,0.0002399883,0.0003345461],"domain_scores_gemma":[0.9989812,0.00008661272,0.0001592872,0.0005198583,0.0001625423,0.00009044814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5685816,0.002093395,0.001490737,0.0001026173,0.0004337008,0.000004014542,0.0002732242,0.0008703541,0.3781163,0.00009366951,0.04771771,0.0002226664],"study_design_scores_gemma":[0.8420053,0.0008971831,0.00009999544,0.00009359744,0.0001118528,0.000006657192,0.0005381313,0.0004101544,0.08204848,0.00002638275,0.07351471,0.0002475881],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9919244,0.0007791943,0.0002600136,0.002896429,0.0003745802,0.003513542,0.000007584065,0.00002974361,0.0002144998],"genre_scores_gemma":[0.9970032,0.00001877663,0.000271413,0.0003012336,0.0002699007,0.0005639465,0.00008841955,0.00002364866,0.001459455],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2960678,"threshold_uncertainty_score":0.9999923,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01076876286501805,"score_gpt":0.2956765989470982,"score_spread":0.2849078360820802,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}